- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/755 - Facteurs VIII
Détention brevets de la classe C07K 14/755
Brevets de cette classe: 827
Historique des publications depuis 10 ans
|
68
|
84
|
65
|
88
|
63
|
53
|
52
|
49
|
40
|
23
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 216 |
85 |
| Takeda Pharmaceutical Company Limited | 2704 |
57 |
| Octapharma AG | 205 |
28 |
| Novo Nordisk A/S | 2287 |
21 |
| The Children's Hospital of Philadelphia | 782 |
17 |
| Baxalta Incorporated | 297 |
15 |
| CSL Behring GmbH | 342 |
15 |
| CSL Limited | 254 |
15 |
| St. Jude Children's Research Hospital | 244 |
15 |
| CSL Behring Lengnau AG | 126 |
15 |
| Bayer HealthCare LLC | 1362 |
14 |
| The Trustees of the University of Pennsylvania | 4308 |
14 |
| Baxalta GmbH | 104 |
13 |
| Emory University | 1619 |
13 |
| Baxter International Inc. | 2380 |
11 |
| Georgia Tech Research Corporation | 2716 |
11 |
| BioMarin Pharmaceutical Inc. | 378 |
11 |
| UCL Business Ltd | 591 |
11 |
| Baxter Healthcare S.A. | 1806 |
10 |
| Spark Therapeutics, Inc. | 164 |
9 |
| Autres propriétaires | 427 |